Rachel M. Golonka

Rachel M. Golonka

Auto-generated profile, based on publicly available information

Rachel M. Golonka

Department of Physiology & Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CCConnor Campbell
Connor Campbell
MKMrunmayee R Kandalgaonkar
Mrunmayee R Kandalgaonkar
RGRachel M. Golonka
Rachel M. Golonka
BYBeng San Yeoh
Beng San Yeoh
MVMatam Vijay-Kumar
Matam Vijay-Kumar
SPSaha Piu
Saha Piu
Gut microbes and their metabolites are actively involved in the development and regulation of host immunity, which can influence disease susceptibility. Herein, we review the most recent research advancements in the gut microbiota–immune axis. We discuss in detail how the gut microbiota is a tipping point for neonatal immune development as indicated by newly uncovered phenomenon, such as maternal imprinting, in utero intestinal metabolome, and weaning reaction. We describe how the gut microbiota shapes both innate and adaptive immunity with emphasis on the metabolites short-chain fatty acids and secondary bile acids. We also comprehensively delineate how disruption in the microbiota–immune axis results in immune-mediated diseases, such as gastrointestinal infections, inflammatory bowel diseases, cardiometabolic disorders (e.g., cardiovascular diseases, diabetes, and hypertension), autoimmunity (e.g., rheumatoid arthritis), hypersensitivity (e.g., asthma and allergies), psychological disorders (e.g., anxiety), and cancer (e.g., colorectal and hepatic). We further encompass the role of fecal microbiota transplantation, probiotics, prebiotics, and dietary polyphenols in reshaping the gut microbiota and their therapeutic potential. Continuing, we examine how the gut microbiota modulates immune therapies, including immune checkpoint inhibitors, JAK inhibitors, and anti-TNF therapies. We lastly mention the current challenges in metagenomics, germ-free models, and microbiota recapitulation to a achieve fundamental understanding for how gut microbiota regulates immunity. Altogether, this review proposes improving immunotherapy efficacy from the perspective of microbiome-targeted interventions.

8 October 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
AAAhmed A. Abokor
Ahmed A. Abokor
GMGrant H. McDaniel
Grant H. McDaniel
RGRachel M. Golonka
Rachel M. Golonka
CCConnor Campbell
Connor Campbell
SBSreya Brahmandam
Sreya Brahmandam
SPSaha Piu
Saha Piu
Mucosal surfaces in the gastrointestinal tract are continually exposed to native, commensal antigens and susceptible to foreign, infectious antigens. Immunoglobulin A (IgA) provides dual humoral responses that create a symbiotic environment for the resident gut microbiota and prevent the invasion of enteric pathogens. This review features recent immunological and microbial studies that elucidate the underlying IgA and microbiota-dependent mechanisms for mutualism at physiological conditions. IgA derailment and concurrent microbiota instability in pathological diseases are also discussed in detail. Highlights of this review underscore that the source of IgA and its structural form can dictate microbiota reactivity to sustain a diverse niche where both host and bacteria benefit. Other important studies emphasize IgA insufficiency can result in the bloom of opportunistic pathogens that encroach the intestinal epithelia and disseminate into circulation. The continual growth of knowledge in these subjects can lead to the development of therapeutics targeting IgA and/or the microbiota to treat life threatening diseases.

7 March 2023 in Gut Microbes
Verified
Journal Article
Open access
MVMatam Vijay-Kumar
Matam Vijay-Kumar
VBVenugopal Bovilla
Venugopal Bovilla
BYBeng San Yeoh
Beng San Yeoh
RGRachel M. Golonka
Rachel M. Golonka
SPSaha Piu
Saha Piu
AGAndrew Gewirtz
Andrew Gewirtz
Intestinal contents comprise the largest repository of immunogenic ligands of microbial origin. We undertook this study to assess the predominant microbe-associated molecular patterns (MAMPs) present therein and the receptors) that mediate the innate immune responses to them. Here, we demonstrated that intestinal contents from conventional, but not germ-free, mice and rats triggered robust innate immune responses in vitro and in vivo. Such immune responses were abrogated in the absence of either myeloid differentiation factor 88 (MyD88) or Toll-like receptor (TLR) 5, but not TLR4, suggesting that the stimuli was flagellin (i.e., protein subunit of flagella that drives bacterial motility). Accordingly, pre-treating intestinal extracts with proteinase, thereby degrading flagellin, was sufficient to block their ability to activate innate immune responses. Taken together, this work serves to underscore flagellin as a major, heat-stable and bioactive MAMP in the intestinal content that confers this milieu strong potential to trigger innate immune responses.

23 May 2023 in Hepatology Communications
Verified
Journal Article
Open access
RGRachel M. Golonka
Rachel M. Golonka
BYBeng San Yeoh
Beng San Yeoh
SPSaha Piu
Saha Piu
AGAmira Gohara
Amira Gohara
RTRamakumar Tummala
Ramakumar Tummala
MVMatam Vijay-Kumar
Matam Vijay-Kumar
Background: HCC is the most common primary liver cancer and a leading cause of cancer-related mortality. Gut microbiota is a large collection of microbes, predominately bacteria, that harbor the gastrointestinal tract. Changes in gut microbiota that deviate from the native composition, that is, “dysbiosis,” is proposed as a probable diagnostic biomarker and a risk factor for HCC. However, whether gut microbiota dysbiosis is a cause or a consequence of HCC is unknown. Methods: To better understand the role of gut microbiota in HCC, mice deficient of toll-like receptor 5 (TLR5, a receptor for bacterial flagellin) as a model of spontaneous gut microbiota dysbiosis were crossed with farnesoid X receptor knockout mice (FxrKO), a genetic model for spontaneous HCC. Male FxrKO/Tlr5KO double knockout (DKO), FxrKO, Tlr5KO, and wild-type (WT) mice were aged to the 16-month HCC time point. Results: Compared with FxrKO mice, DKO mice had more severe hepatooncogenesis at the gross, histological, and transcript levels and this was associated with pronounced cholestatic liver injury. The bile acid dysmetabolism in FxrKO mice became more aberrant in the absence of TLR5 due in part to suppression of bile acid secretion and enhanced cholestasis. Out of the 14 enriched taxon signatures seen in the DKO gut microbiota, 50% were dominated by the Proteobacteria phylum with expansion of the gut pathobiont γ-Proteobacteria that is implicated in HCC. Conclusions: Collectively, introducing gut microbiota dysbiosis by TLR5 deletion exacerbated hepatocarcinogenesis in the FxrKO mouse model.

28 January 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RGRachel M. Golonka
Rachel M. Golonka
LILauren E. Intravaia
Lauren E. Intravaia
ASAla M. Shaqra
Ala M. Shaqra
QLQi Li
Qi Li
YCYongzhi Chen
Yongzhi Chen
LCLisa Cavacini
Lisa Cavacini
The COVID-19 pandemic accelerated the development of monoclonal antibodies (mAb) targeting SARS-CoV-2, with IgG1-based mAbs dominating the therapeutic landscape. However, IgA-the predominant immunoglobulin at mucosal surfaces-represents a promising alternative for respiratory infections due to its natural role in immune exclusion and pathogen neutralization. Here, we engineered IgA-Fc fusion proteins conjugated with nanobodies (VHH-IgA) derived from immunized llamas to neutralize SARS-CoV-2 variants. Phage display libraries generated from Delta and Omicron receptor-binding domain (RBD) immunized llamas yielded 248 unique VHH sequences, with fifty candidates selected based on binding reactivity and neutralization potency. VHH-IgA fusion proteins were expressed in Expi293 cells, and top candidates exhibited high binding affinities (EC50 < 0.2 nM) and potent neutralization (IC50 < 40 pM) against multiple SARS-CoV-2 variants, including Omicron Ba.1 and XBB. Structural modeling predicted that the leading VHH-IgA candidates 2D4, 1C2, and 2D10 adopt distinct binding conformations to accommodate amino acid sequence variations on the Omicron RBD domain. In vitro assays demonstrated that 2D4, 1C2, and 2D10 neutralized authentic Omicron variants of concern, with 2D4 exhibiting the broadest activity. In vivo, intranasal administration of 2D4 VHH-IgA significantly reduced SARS-CoV-2 XBB viral loads in the lungs of infected K18-hACE2 mice. These findings highlight the therapeutic potential of IgA-based nanobody fusion proteins as mucosal antivirals against SARS-CoV-2. Our work positions VHH-IgA fusion proteins as a platform for developing next-generation biologics to combat respiratory pathogens at mucosal surfaces.

16 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
PCPiotr J Czernik
Piotr J Czernik
RGRachel M Golonka
Rachel M Golonka
SCSaroj Chakraborty
Saroj Chakraborty
BYBeng San Yeoh
Beng San Yeoh
AAA Abokor
A Abokor
APAndrew Patterson
Andrew Patterson
In recent years there has been growing evidence regarding the effect of microbiota on the skeletal growth and homeostasis. Here we present, for the first time, accelerated longitudinal and radial bone growth in young (7-week-old) germ-free male rats after short-term exposure to a newly established gut microbiota. Changes in bone mass and structure were analyzed after 10 days following the onset of colonization through cohousing with conventional rats and revealed unprecedented acceleration of bone accrual in cortical and trabecular compartments, increased bone tissue mineral density, improved proliferation and hypertrophy of growth plate chondrocytes, bone lengthening, and preferential deposition of periosteal bone in tibia diaphysis. In addition, the number of small-in-size adipocytes increased, while the number of megakaryocytes decreased, in the bone marrow of conventionalized germ-free rats. The observed changes in bone status were paralleled with a positive shift in microbiota composition towards short chain fatty acids (SCFA)-producing microbes, which reflected a dramatic increase in cecal concentration of SCFA, specifically butyrate. Further, reconstitution of the host holobiont increased hepatic expression of IGF-1 and its circulating levels, implicating an involvement of the somatotropic axis. Increased serum levels of 25-hydroxy vitamin D and alkaline phosphatase pointed toward an active process of bone formation. The acute stimulatory effect on bone growth occurred independently of body mass increase and resembled reversal of dysbiosis in adolescence, which is marked by rapid skeletal expansion. These findings may help in developing microbiota-based therapeutics to combat bone related disorders resulting from hormonal defects and/or malnutrition in children and adolescence.